Abviva Announces Letter of Intent to Acquire Prion Developmental Laboratories

Abviva, Inc. (f/k/a Genesis Bioventures: OTCBB:GBIW) today announced that it has entered into a Letter of Intent with the Receiver for Efoora, Inc. appointed by the United States District Court For The Northern District of Illinois Eastern Division (the "Court”) to acquire all Prion Developmental Laboratories, ("PDL”) stock owned by Efoora, Inc., PDL’s current majority owner. The acquisition is subject to Abviva’s due diligence, final approval by Abviva’s Board of Directors and entry of an order approving the sale by the Court. Genesis Bioventures, Inc. originally announced on July 25, 2006 that it signed a Letter of Intent with PDL to acquire the assets of PDL. At the time the Letter of Intent was signed the Company was a minority shareholder of PDL. Two days later on July 27, 2006 the United States Securities And Exchange Commission (the "SEC”) contacted the Company and informed it that the Court had issued a Freeze Order (S.E.C. vs. Efoora, Inc, et. al., No. 06 C 3526 (N.D. Ill., June 29, 2006)) on certain of the assets of Efoora, Inc. in conjunction with the SEC’s actions against Efoora, Inc. The Freeze Order also extended to certain of the assets of PDL. The Company’s management and corporate counsel, Richardson & Patel, LLP, immediately contacted the SEC and initiated a dialogue regarding the potential acquisition of PDL. The SEC filed a motion on June 20, 2007 to appoint a receiver (the "Receiver”) for Efoora, Inc. The motion was approved by the Court. The Company and the Receiver began discussions to negotiate the acquisition of the PDL stock by the Company. Those discussions resulted in the Letter of Intent signed by the Receiver and the Company, effective November 27, 2007. "We are very pleased that the Receiver has agreed to allow us to continue with the acquisition of PDL under the terms and conditions we agreed to in the Letter of Intent,” said Douglas C. Lane, Abviva President and CEO. "During the last seventeen months since we learned of the asset freeze of PDL and Efoora we have worked diligently to preserve PDL and its BSE (Mad Cow Disease) Rapid Assay product opportunity. Though we were a minority shareholder it was obvious to us that if we did not take the senior support and management responsibility for PDL the company and our substantial investments in the company and the products would be lost.” The Company announced at its 2007 Annual Shareholder Meeting that the Company intends to focus its business on breast cancer diagnostics and therapeutics. The Company also stated that it will continue its commitment to add value to the Company’s substantial investments in PDL. The Company believes it is in the best interest of the Company and the Company’s investors and shareholders that it continues with the acquisition. Once PDL is a majority owned stand-alone company the Company will have several strategic alternatives available to it that management can use to facilitate the Company’s focus on breast cancer diagnostics and therapeutics that the Company believes will further increase the Company’s value. About Abviva, Inc. Abviva is a biomedical company focused on the commercialization of its owned and licensed assets for breast cancer diagnostics and for breast cancer therapeutic development. About Prion Developmental Laboratories PDL is a biotechnology company that researches, develops and produces advanced diagnostic and food safety monitoring tests for human and animal diseases caused by prions. Abviva, Inc. has a significant investment in PDL. Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.